Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301. AR-301 is being developed as an adjunctive therapy with standard-of-care (SOC) antibiotics for pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitalized patients. Key agreements by the EMA were similar to those a
ClearwinUS Launches Effective Bacteria Elimination Solutions thomasnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thomasnet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -0.4% from.